title: Hodgkin lymphoma, version 2.2015.
abstract: Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.
authors.forename: Richard T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.forename: Weiyun Z
authors.initials: WZ
authors.lastname: Ai
authors.forename: Richard F
authors.initials: RF
authors.lastname: Ambinder
authors.forename: Patricia
authors.initials: P
authors.lastname: Aoun
authors.forename: Celeste M
authors.initials: CM
authors.lastname: Bello
authors.forename: Cecil M
authors.initials: CM
authors.lastname: Benitez
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: Kristie A
authors.initials: KA
authors.lastname: Blum
authors.forename: Robert
authors.initials: R
authors.lastname: Chen
authors.forename: Bouthaina
authors.initials: B
authors.lastname: Dabaja
authors.forename: Andres
authors.initials: A
authors.lastname: Forero
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Hernandez-Ilizaliturri
authors.forename: Ephraim P
authors.initials: EP
authors.lastname: Hochberg
authors.forename: Jiayi
authors.initials: J
authors.lastname: Huang
authors.forename: Patrick B
authors.initials: PB
authors.lastname: Johnston
authors.forename: Nadia
authors.initials: N
authors.lastname: Khan
authors.forename: David G
authors.initials: DG
authors.lastname: Maloney
authors.forename: Peter M
authors.initials: PM
authors.lastname: Mauch
authors.forename: Monika
authors.initials: M
authors.lastname: Metzger
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Moore
authors.forename: David
authors.initials: D
authors.lastname: Morgan
authors.forename: Craig H
authors.initials: CH
authors.lastname: Moskowitz
authors.forename: Carolyn
authors.initials: C
authors.lastname: Mulroney
authors.forename: Matthew
authors.initials: M
authors.lastname: Poppe
authors.forename: Rachel
authors.initials: R
authors.lastname: Rabinovitch
authors.forename: Stuart
authors.initials: S
authors.lastname: Seropian
authors.forename: Christina
authors.initials: C
authors.lastname: Tsien
authors.forename: Jane N
authors.initials: JN
authors.lastname: Winter
authors.forename: Joachim
authors.initials: J
authors.lastname: Yahalom
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Burns
authors.forename: Hema
authors.initials: H
authors.lastname: Sundar
mesh_terms: D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D012008:Recurrence